| pubmed-article:15173002 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C0023418 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C0546881 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C0079411 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C0521115 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:15173002 | lifeskim:mentions | umls-concept:C2348480 | lld:lifeskim |
| pubmed-article:15173002 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:15173002 | pubmed:dateCreated | 2004-6-2 | lld:pubmed |
| pubmed-article:15173002 | pubmed:abstractText | To determine the mechanisms by which adoptive immunotherapy could reduce lethality to acute myelogenous leukemia (AML), a novel technique was developed to track both leukemic blasts and adoptively transferred cytotoxic T cells (CTLs) independently and simultaneously in mice. To follow the fate of ex vivo generated anti-AML-reactive CTLs, splenocytes obtained from enhanced green fluorescent protein transgenic mice were cocultured with AML lysate-pulsed dendritic cells, which subsequently were expanded by exposure to anti-CD3/CD28 monoclonal antibody-coated magnetic microspheres. To track AML cells, stable transfectants of C1498 expressing DsRed2, a red fluorescent protein, were generated. Three factors related to CTLs correlated with disease-free survival: (a). CTL L-selectin expression. L-Selectin high fractions resulted in 70% disease-free survival, whereas L-selectin low-expressing CTLs resulted in only 30% disease-free survival. (b). Duration of ex vivo expansion (9 versus 16 days). Short-term expanded CTLs could be found at high frequency in lymphoid organs for longer than 4 weeks after transfer, whereas long-term expanded CTLs were cleared from the system after 2 weeks. Duration of expansion correlated inversely with L-selectin expression. (c). CTL dose. A higher dose (40 versus 5 x 10(6)) resulted in superior disease-free survival. This survival advantage was achieved with short-term expanded CTLs only. The site of treatment failure was mainly the central nervous system where no CTLs could be identified at AML sites. | lld:pubmed |
| pubmed-article:15173002 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15173002 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15173002 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15173002 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15173002 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15173002 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15173002 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15173002 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15173002 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15173002 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15173002 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:JuneCarl HCH | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:LevineBruce... | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:BlazarBruce... | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:TaylorPatrici... | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:KrenBetsy TBT | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:Panoskaltsis-... | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:WeigelBrenda... | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:SauerMartin... | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:EricsonMarna... | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:HerronMichael... | lld:pubmed |
| pubmed-article:15173002 | pubmed:author | pubmed-author:SerodyJon SJS | lld:pubmed |
| pubmed-article:15173002 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15173002 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:15173002 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:15173002 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15173002 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15173002 | pubmed:pagination | 3914-21 | lld:pubmed |
| pubmed-article:15173002 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:meshHeading | pubmed-meshheading:15173002... | lld:pubmed |
| pubmed-article:15173002 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15173002 | pubmed:articleTitle | A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. | lld:pubmed |
| pubmed-article:15173002 | pubmed:affiliation | University of Minnesota Cancer Center and Department of Pediatrics, Minneapolis, Minnesota 55455, USA. | lld:pubmed |
| pubmed-article:15173002 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15173002 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15173002 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15173002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15173002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15173002 | lld:pubmed |
